Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Authors:
Open Access
- 18 May 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 35 (6) , 1605-1618
Abstract
Chronic kidney disease (CKD) is a global health problem, affecting more than 850 million people worldwide. The number of patients receiving renal replacement therapy (dialysis or renal transplantation) has increased over the years, and it has been estimated that the number of people receiving renal replacement therapy will more than double from 2.618 million in 2010 to 5.439 million in 2030, with wide differences among countries. The main focus of CKD treatment has now become preserving renal function rather than replacing it. This is possible, at least to some extent, through the optimal use of multifactorial therapy aimed at preventing end-stage kidney disease and cardiovascular events. Sodium/glucose cotransporter 2 inhibitors (SGLT2i) reduce glomerular hypertension and albuminuria with beneficial effects on progression of renal damage in both diabetic and non-diabetic CKD. SGLT2 inhibitors also show great benefits in cardiovascular protection, irrespective of diabetes. Therefore, the use of these drugs will likely be extended to the whole CKD population as a new standard of care. Graphical abstractKeywords
Funding Information
- Università degli Studi di Milano
- AstraZeneca ITA
This publication has 81 references indexed in Scilit:
- Prognosis of CKD Patients Receiving Outpatient Nephrology Care in ItalyClinical Journal of the American Society of Nephrology, 2011
- CKD Awareness and Blood Pressure Control in the Primary Care Hypertensive PopulationAmerican Journal of Kidney Diseases, 2011
- Chronic kidney disease: a public health priority and harbinger of premature cardiovascular diseaseJournal of Internal Medicine, 2010
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Acute Phosphate Nephropathy following Oral Sodium Phosphate Bowel PurgativeJournal of the American Society of Nephrology, 2005
- Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2005
- Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indicationsKidney International, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Retarding the progression of renal diseaseKidney International, 2003
- Understanding the nature of renal disease progressionKidney International, 1997